Clin2
NCT04793685Possibly a fitRecruiting

Prazosin for alcohol withdrawal symptoms in alcohol use disorder

Alcohol Withdrawal

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This study tests whether prazosin can reduce symptoms that happen when someone stops or cuts back on heavy drinking. It may help people with moderate-to-severe alcohol use disorder who also have alcohol withdrawal symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
150 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must currently have alcohol withdrawal symptoms (based on a withdrawal score or symptom check) when you start the study
  • You must meet diagnostic criteria for moderate-to-severe alcohol use disorder
  • You must be able to read English, answer study questionnaires, and understand consent
  • You cannot have other drug use disorders (except nicotine, and sometimes limited cannabis/cocaine rules as listed) that would interfere with the study
  • You must not be on certain medicines that affect the brain or blood pressure in ways that conflict with prazosin

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07444255Not yet recruiting
Hypnosis and aromatherapy for anxiety during alcohol withdrawal

This trial tests whether combining hypnosis with aromatherapy (using calming scents) can help reduce anxiety better than standard care for people going through alcohol withdrawal. It aims to find a gentler, drug-free way to manage anxiety during detox.

Strasbourg
NCT05781009Recruiting· Phase 2
Pregnenolone treatment for alcohol use disorder

This Phase 2 study tests pregnenolone to help reduce or improve alcohol use disorder symptoms. It looks for adults who drink regularly and meet diagnostic criteria for moderate to severe alcohol use disorder, while excluding people with certain other substance use, medicines, or serious mental/medical conditions.

New Haven, Connecticut
NCT04135846Recruiting· Phase 2
Alpha-blocker medicine to help reduce alcohol drinking

This Phase 2 trial tests whether blocking certain body signals (alpha receptors) with a study medicine can help people with alcohol use disorder cut down or stop drinking. You may be able to join if you meet alcohol-use criteria and can safely take the study drug.

Providence, Rhode Island
NCT04084860Recruiting· Phase 2
Brief medicine trial to help reduce heavy alcohol drinking

This Phase 2 study tests a brief medication approach meant to reduce “problem drinking.” It may help people cut back or stop alcohol use by adjusting brain signaling related to drinking cravings and urges.

New York, New York
NCT03764098Recruiting· Phase 2
Guanfacine to reduce heavy drinking in adults with alcohol use disorder

This Phase 2 study tests whether guanfacine can reduce drinking in women and men who drink heavily and meet criteria for alcohol use disorder. It also looks at how the medicine affects drinking patterns in a controlled setting.

New Haven, Connecticut
NCT05827159Recruiting· Phase 3
Medications started in the ER for alcohol use disorder

This study tests whether starting certain medications in the emergency room can help people with moderate to severe alcohol use disorder reduce heavy drinking and withdrawal problems after they leave the ER. It compares outcomes for participants who receive the study medications soon after an ER visit.

New Haven, Connecticut

Hear when a new Alcohol Withdrawal trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.